Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Ricardo Correa-Rotter et al.|The Lancet|2019Cited by 609
Supplementary Material for: A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal DiseaseMatthew R. Weir, Radmila Kančeva, Pablo E. Pérgola et al.|Figshare|2017Cited by 0